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The "promoting" activity of methyl methanesulphonate in
rat bladder carcinogenesis
R.J. Tudor, N.J. Severs* & R.M. Hicks
School ofPathology, The Middlesex Hospital Medical School, London WIP 7LD, UK.
Summary The carcinogenic activity of the alkylating agent methyl methanesulphonate (MMS) was
investigated in the F344 rat bladder, both untreated and pretreated with a single threshold dose of N-methyl-
N-nitrosourea (MNU). On its own, 6 doses of 2.5mg MMS produced a 7% incidence of bladder cancer.
After a single intravesical instillation of MNU, the same MMS treatment produced a bladder cancer incidence
of 56%. This was significantly higher than the incidence (24%) observed after treatment with MNU alone,
and greater than the sum of the lesions produced by either treatment alone. By reference to the mouse skin
multistage carcinogenesis model, it is argued that MMS is a complete, albeit weak carcinogen with little
initiating but powerful late-stage activity. Its promoting activity is most probably attributable to its potent
mitogenic action and in this model it is analogous to a stage 2, rather than a stage 1 skin promoter.
The alkylating agent, methyl methanesulphonate
(MMS) is cytotoxic and produces regenerative
urothelial hyperplasia when instilled directly into
the rat bladder (Wakefield & Hicks, 1974; Tudor et
al., 1983). Recently, we showed that over longer
periods, multiple doses of MMS induce a milder
but more persistent urothelial hyperplasia with little
or no dysplasia (Tudor et al., 1983). In addition,
fotur well-differentiated lesions with abnormal
growth patterns were observed (either
papillary/nodular hyperplasia or papillary
carcinoma), but their occurrence was not dose-
related.
We suggested that these findings did not
necessarily reflect an initiating potential of MMS,
but rather indicated that MMS could act as a
promoter or late-stage carcinogen either in
previously initiated cells or in cells carrying a latent
oncogene.
The present study was undertaken to investigate
whether multiple doses of MMS can indeed
promote tumour development in previously
initiated rat bladder. A low dose of N-methyl-N-
nitrosourea (MNU) was used as the initiating
agent.
Materials and methods
rooms maintained at 19-22°C with a relative
humidity of 50-60% and 12h of artificial light
during the daytime. Basic diet was Dixon's 41B
containing 1.03% calcium, 0.53% phosphorus and
0.21% magnesium (E. Dixon and Co., Ware,
Hertfordshire) and drinking water was taken from
the mains supply; both were available ad libitum.
The animals were 6-8 weeks old at the beginning of
treatment, and were killed after 2 years or earlier if
they appeared moribund or developed symptoms
such as haematuria or a palpable pelvic mass.
Chemicals
MNU was synthesized by Dr A.K. Wallis in the
Courtauld Institute of Biochemistry, Middlesex
Hospital Medical School, by the method of Werner
(1919). Its purity was checked by melting-point
determination and high pressure liquid
chromatography as detailed previously (Severs et
al., 1982). MMS was obtained from Cambrian
Chemicals Ltd., Croydon, Surrey and used as
supplied. Small, preweighed aliquots of both
chemicals were stored in light-proof, screw-capped
vials at -20°C.
Preparation ofchemicals
Animals
SPF female F344 rats weighing 120-150 g were
supplied by Bantin and Kingman Ltd., Hull, North
Humberside. These were caged in groups of 6 in
MNU A preweighed aliquot of MNU was
brought overnight to 4°C. A measured volume of
Mcllvaine's citric acid/phosphate buffer (pH 7.0)
was added to give a final MNU concentration of
3mgml-1. The solution was stirred in the re-sealed
vial with a magnetic flea for 5 min to ensure rapid
dissolution. The resulting solution was used for
intravesical dosing of animals during the next 30
minutes only and the residue then discarded into
1M NaOH solution.
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MMS: Each preweighed aliquot of MMS was
brought overnight to 4°C. A predetermined volume
of McIlvaine's buffer (pH 7.0) was added to give a
final concentration of 25mgml- 1. The solution was
stirred for 5min using a magnetic flea and then
used for intravesical dosing for the next 60min
only.
Intravesical dosing
Urethral catheters were made from 4cm lengths of
0.7mm plastic tubing (pp-IO, Portex Ltd., Hythe,
Kent) and sterilized in 70% ethanol overnight. Rats
were anaesthetized by intraperitoneal veterinary
nembutal (May and Baker Ltd., Dagenham, Essex),
and a catheter inserted via the urethra into the
bladder of each animal. Micturition was induced by
gentle pressure to the lower abdomen in order to
minimise dilution of MNU or MMS by urine in the
bladder. The concentration of both MNU and
MMS solutions were selected such that the required
dose of each could be instilled in a volume of
0.1 cm3. The agents were administered using a
graduated syringe with a 30G needle which fitted
into the end of the catheter. After dosing the
catheters were gently withdrawn from each bladder
and the animals returned to cages where they were
kept warm during recovery.
Experimental design
Animals were randomly divided into 4 groups (A-
D). Animals in group A were not treated and were
maintained as the control group. Rats in group B
received a single intravesical dose of 0.3 mg MNU.
Those in group C were instilled with 6 separate
intravesical doses of 2.5 mg MMS, each dose
administered at an interval of 14 days. Animals in
group D received a single intravesical dose of
0.3mg MNU followed 14 days later by the first of
6 intravesical instillations of 2.5mg MMS given at
2 week intervals (see Table I for details).
Post-mortem procedures and tissue preparation
Animals that appeared moribund or developed
signs indicative of bladder neoplasia, and those
surviving to two years after the initial dose were
killed by cervical dislocation. Animals found dead
during the study were autopsied unless cannibalised
or badly autolysed.
Theurinary bladder wasexposed, emptied bygentle
pressure if necessary and, after clamping the urethra,
inflated with 0.5cm3 of 10% phosphate-buffered
formaldehyde (pH 7.4) injected through the dome
using a fine needle. The serosal surface of the
bladder was bathed with the same fixative and after
4 minutes fixation in situ, the bladder was excised.
The bladder was bisected longitudinally and the
luminal surface examined under a dissecting
microscope for macroscopic abnormalities (e.g.
thickened areas, papillary growths or calculi). In
bladders of normal macroscopic appearance, one
half was further fixed in 10% formaldehyde for
standard wax histology. The other half was cut into
mm3 blocks and postfixed in cold 0.1 M
cacodylate-buffered 1% osmium tetroxide. After
dehydration the tissue was embedded in Spurr resin
and semi-thin (1gm) sections were cut and stained
with toluidine blue for high resolution light
microscopy. At least 3 blocks from each bladder
were examined to complement the results obtained
by conventional histology.
In thickened or tumour-bearing bladders,
representative samples of each thickened area or
tumour were prepared for both wax and resin
embedding. Bladders from animals found dead were
processed for wax histology only. Other organs
were examined for gross abnormalities, and the
kidneys and liver routinely processed for histology.
Results
Bladder pathology
The terminal bladder pathology is shown in Tables
Table I Terminal pathology of the urothelium
Urothelial histology
(% incidence shown in parenthesis)
No. ofbladders? Hyperplastic
Group Treatment examined Normal Mild moderate P/Nb Neoplastic
A Untreated 25 20(80) 4(16) 1(4)
B MNU alone 29 7(24) 7(24) 5(18) 3(10) 7(24)
C 6xMMS 27 7(26) 13(48) 5(19) - 2(7)
D MNU+6xMMS 33 2(6) 6(18) 6(18) 19(58)C
aBladders were from rats surviving to 2 years after the initial dose plus those killed in extremis or
found dead after detection of the first bladder tumour at 60 weeks.
bP/N refers to urothelial hyperplasias with a papillary/nodular growth pattern.
cP<0.02 for groups D vs B - chi-squared test (with Yates correction).
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I and II. The criteria used in the diagnosis
of urothelial lesions are those currently in use in this
laboratory and have been published previously
(Hicks et al., 1982; Tudor et al., 1983).
Group A: Untreated controls The majority of
untreated control bladders had a normal
urothelium (Figure 1, Table I). Mild focal hyper-
plasia was seen in 4, the lesions being well- Oo
differentiated with flattened but not necessarily
mature superficial cells. In a fifth bladder, a diffuse
urothelial hyperplasia, varying in severity from mild
to moderate in nature, was observed (Figure 2a). A
single focal area of cystitis cystica was also present
(Figure 2b) and early vascular infiltration of the
urothelium was apparent. Much of the hyperplastic
urothelium in this bladder failed to mature and the e ilI e.
epithelium consisted primarily of small, basal-type
cells (Figure 2c). 0
Alterations in normal urothelial differentiation, En
such as disorientation of nuclei or irregular nuclear . <
profiles, were rarely seen in urothelia from the -_
control group. The urothelium in the trigone region -
of control rat bladders is commonly four cells
thick, whereas elsewhere there are three cell layers,
and this has been taken into account during o
assessment of bladders from the treated groups.
0 cd
Group B: MNU alone In animals that received a
single dose of MNU, urothelial lesions were found E
in 76% of the bladders (Table I). In addition to . : I- _i
well-differentiated flat hyperplasias there were two 8 . Q
papillary hyperplasias with exophytic proliferation
of blood vessels towards the bladder lumen, and X
one nodular hyperplasia. . i ItI o
Foci of mild dysplasia were common following
MNU treatment, both in urothelia of normal
thickness and in hyperplastic tissues. The dysplasias 3 X - -
were characterised by nuclear disorientation and Cd
pleomorphic nuclei in the basal and intermediate
cell layers. The profiles of involved nuclei were X I
commonly irregular, showing indentation or C
invagination. D
Seven transitional cell carcinomas developed, all ; o o
with a papillary, exophytic growth pattern (Table
II). Five of these were simple, papillary carcinomas > "
with invasion of the papillary stalk (Pla) although .
one also showed an early focus of squamous z . = = - .
metaplasia. A further neoplasm was diagnosed as E - e ,o + ; X
carcinoma in situ within a papillary hyperplasia. ° 0 cd D
However, the most severe urothelial changes > z
observed in this treatment group were in a bladder Q m
containing two separate papillary tumours. The
smaller carcinoma showed Pla invasion, but in the
other, which was a very large exophytic lesion
(4.5cm x 2.5cm) there was invasion of transitional
cells into the underlying lamina propria adjacent to
the stalk (Plb invasion), extensive necrosis,66 R.J. TUDOR et al.
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Figure 1 Urothelium from an untreated control rat, showing normal differentiation into basal, intermediate
and superficial cell layers. Toluidine blue-stained semi-thin section. x 475.
Figure 2 Diffuse urothelial hyperplasia in an untreated control. A survey view is shown in (a); enlargements
of the selected areas show detail of cystitis cystica (b) and moderate hyperplasia (c). H & E-stained wax
section. (a) x 90; (b) x 460; (c) x 425.
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haemorrhage and squamous metaplasia (Figure 3).
There was also early mineralization of necrotic
tumour tissue.
Group C. MMS alone In animals that received six
doses of MMS, urothelial hyperplasias were also
numerous, affecting 68% of the animals (Table I).
Although most were mild and focal, moderate
simple hyperplasia was present in five animals. All
hyperplasias were differentiated, but in the more
severe lesions the superficial cells often appeared
rounded and immature. Mild urothelial dysplasias
were less severe than those produced by MNU
alone and were notably less frequent.
Two transitional cell carcinomas were detected in
animals from this group (Table II). One was a large
exophytic papillary tumour very comparable to that
illustrated previously in an MMS-treated animal
(Tudor et al., 1983). It had early invasion of the
underlying lamina propria (Plb) and a small area of
squamous metaplasia. A large, single free-lying
calculus was present within this bladder. The other
neoplasm had a different growth pattern with an
inverted papillary structure invading the underlying
lamina propria (Figures 4a, 4b), and extensive
squamous metaplasia at the luminal surface. The
tumour had obstructed the bladder neck and the
resulting urinary stasis had caused severe cystitis,
haemorrhage and necrosis of all tissue layers.
Group D. MNU+6 x MMS In this group, few
bladders had normal urothelia. Mild and moderate
simple hyperplasias were numerous, but no
papillary or nodular hyperplasias were observed,
except in tumour-bearing bladders. The simple
hyperplasias were generally less well-differentiated
than similar lesions in other treatment groups, with
a loss of cellular organization and frequent absence
of differentiated superficial cells. Foci of mild
urothelial dysplasia were also more common than
in other groups (Figure 5). In addition, occasional
more severe dysplasia was observed, characterized
by considerable variation in size, shape and staining
density of nuclei, loss of normal cell and nuclear
polarity and the presence of highly irregular nuclear
profiles (Figure 6).
Transitional cell carcinoma was the most
frequent urothelial lesion observed in this group,
accounting for 58% of the bladders examined
(Figure 7, Table II). Papillary transitional cell
carcinomas were recorded in 17 bladders with
invasion of the lamina propria (Plb) in seven
(Figure 8). Generally, the histopathology of these
lesions was more severe than that produced by
MNU or MMS alone (Figures 9-11). Multifocal
papillary neoplasias were observed in three bladders
and squamous metaplasia in four. Two other
bladders had foci of carcinoma in situ within areas
of either papillary or nodular urothelial hyperplasia
(Figure 12).
Pathology ofother organs
Neoplastic and non-neoplastic lesions observed in
organs other than the bladder were similar to those
reported previously in F344 rats (Sass et al., 1975;
Figure 3 Part of a large exophytic transitional cell carcinoma from an MNU-treated animal, showing
stromal invasion by nests of poorly differentiated transitional cells, and early squamous metaplasia (arrows).
H & E-stained wax section. x 110.68 R.J. TUDOR et al.
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Figure 4 Transitional cell carcinoma with an inverted papillary growth pattern from an MMS-treated rat. (a)
Survey view shows invasive tongues of transitional cells, an area of squamous metaplasia, and inflammation
and necrosis at the luminal surface. (b) Higher magnification of area shown in (a); moderately differentiated
transitional cells, arrows indicate mitotic figures. Note inflammation at the luminal surface. H & E-stained
wax section. (a) x 110; (b) x 425.METHYL METHANESULPHONATE AND BLADDER CARCINOGENESIS 69
Figure 5 Mild urothelial dysplasia from an animal treated with MNU+6 x MMS. Note multinucleate cells, irregular nuclear profiles and disorientated nuclei of variable size. Toluidine blue-stained semi-thin section. x 680.
Figure 6 Severe urothelial dysplasia in a tumour-bearing bladder from an animal treated with MNU+6xMMS. Atypical transitional cells with marked pleomorphism, loss of polarity, hyperchromasia and reduction in intercellular cohesion. This area was not classified as carcinoma-in-situ, as no mitoses could be seen. Toluidine blue-stained semi-thin section. x 270.
Figure 7 Low power view of a typical papillary transitional cell carcinoma from an animal treated with MNU+6 x MMS. H & E-stained wax section. x 17.
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Figure 8 Clusters ofinvasive transitional cells within the lamina propria of the bladder wall from a papillary
carcinoma similar to that in Figure 7. The base of the tumour stalk lies to the right of the field. H & E-
stained wax section. x 230.
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Figure 9 Part of a papillary transitional cell carcinoma with moderate differentiation from an animal treated
with MNU+6 x MMS. Pleomorphic nuclei, loss of polarity and hyperchromicity are obvious. Cytoplasmic
vacuolation is also apparent. Toluidine blue-stained semi-thin section. x 170.METHYL METHANESULPHONATE AND BLADDER CARCINOGENESIS
Figure 10 High power view of a high grade (poorly differentiated) papillary transitional cell carcinoma from an animal treated with MNU+6xMMS. The tumour consists primarily of small dark cells arranged in circular clusters with no obvious transitional cell features. Toluidine blue-stained semi-thin section. x 260.
Coleman et al., 1977; Goodman et al., 1979). None
of these lesions was treatment-related.
All animals had some degree of renal pathology.
Ninety-eight percent ofkidneys were affected by the
degenerative lesion "chronic nephropathy"
(Coleman et al., 1977). Frequently chronic
interstitial nephritis was present in these affected
kidneys. Other occasional changes included small
foci of cortico-medullary mineralization and hyper-
plasia of the pelvic transitional epithelium. In one
animal from group D (MNU+6 x MMS) an
irregularly shaped calculus was associated with a
transitional cell carcinoma of the pelvic epithelium
and ureter proximal to the kidney. The bladder
from the same animal contained multifocal
transitional cell carcinomas.
Much of the hepatic material examined was
normal, although bile-duct hyperplasia usually
with concurrent sclerosis, was observed in 38% of
animals. Other occasional focal hepatic lesions
included necrosis, fatty change and chronic
hepatitis. No hyperplastic nodules or hepatic
neoplasms were detected.
Gross lesions observed in other tissues taken at
post-mortem and subsequently examined histo-
logically, were similar to those previously reported
and appear to be characteristic for the F344 rat
D
(Goodman et al., 1979). Fibroadenoma of the
mammary gland (13%), endometrial stromal polyps
of the uterus (9%) and atypical mononuclear cell
leukaemia (17%) were the most common. Other
occasional lesions included fibroma of the subcutis,
adenoma of the clitoral gland and carcinoma of the
uterus.
Discussion
Detailed studies of chemical carcinogenesis in the
mouse skin model have demonstrated a multistage
process involving discrete stages of initiation, Stage
1 promotion, Stage 2 promotion and malignant
conversion (Slaga, 1983). Initiation involves a rapid
interaction of the carcinogen with target cell DNA
to produce a mutagenic change; the initiated cell
then carries an altered genotype although its
phenotype is unchanged. Stage 1 promoters alter
the pattern of gene expression by speciflcally
binding to and activating a lipid-dependent protein
kinase in the cell membrane, thus catalysing a
cascade of metabolic changes within the cell
(Weinstein, 1983). This permits expression of the
tumour phenotype thus conferring an altered
proliferative capacity upon these premalignant cells.
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Figure 11 Part of a large papillary transitional cell carcinoma with a variable growth pattern and diverse
differentiation from a rat treated with MNU+6 x MMS. Large, polyp-like outgrowths are covered by
dysplastic, nodular urothelium. There is invasion of epithelial cells into the stroma and a large area of
squamous metaplasia with associated keratinization. H & E-stained wax section. x 17.
Figure 12 Carcinoma-in-situ in an area of raised nodular hyperplasia from an animal treated with
MNU+6 x MMS. Note increased cellularity with disorientated pleomorphic cells and the presence of several
mitoses (arrows). H & E-stained wax section. x 170.METHYL METHANESULPHONATE AND BLADDER CARCINOGENESIS 73
Stage 2 promoters cause selective proliferation
(clonal expansion) of the premalignant cells
resulting in the development of benign tumours.
Stage 2 promoters are all hyperplastic agents and
repeated exposure is required to sustain the
proliferative stimulus which permits the
preneoplastic cells to grow at the expense of their
uninitiated neighbours. Many mitogens can act as
Stage 2 promoters, but unless they can also bring
about Stage 1 events, they will be incomplete
promoters and will not produce tumours from
initiated cells. The final malignant conversion of a
benign tumour of premalignant cells into an
invasive cancer requires another specific genetic
event, probably translocation of genetic material
rather than a point mutation such as occurs during
initiation (Moolgavkar & Knudson, 1981).
The biological and pathological events associated
with promotion in skin and other tissues have been
reviewed recently (Hicks, 1983a). In experimental
bladder cancer models, sodium cyclamate, sodium
saccharin, phenacetin and tryptophan all
significantly increase the incidence of bladder
cancer in rats previously treated with threshold
doses of bladder carcinogens (Hicks, 1983b). Such
compounds act as late-stage carcinogens and
accelerate the development of transitional cell
carcinoma in carcinogen-treated urothelia. Because
they have the ability to increase tumour yield above
that produced by a low dose of carcinogen alone,
they have been regarded as promoters, but the data
supporting the possibility that they have stage 1
promoting activity is not conclusive (Hicks, 1983b).
With one exception (Hicks et al., 1975), the
carcinogen in these studies was not used at a sub-
threshold or initiating dose, but at a level sufficient
to produce a few neoplasms on its own.
Furthermore, there is no biochemical evidence that
these agents activate protein kinase C to catalyse
stage 1 promoting events in the bladder analogous
to those produced, for example, by TPA in the
skin. The published evidence is more consistent
with these compounds acting as Stage 2 promoters,
by supplying the proliferative stimulus necessary for
clonal expansion. The role of MMS in bladder
carcinogenesis reported here is evaluated in the
light of these considerations.
The results (Tables I and II) demonstrate that
MMS significantly increases the incidence of
urothelial neoplasms in MNU-pretreated bladders
by comparison with the number produced by MNU
only. Furthermore, this increase far exceeds the
sum of the numbers produced by either MNU or
MMS alone. In addition, subsequent treatment with
MMS reduced the time to detection of the first
MNU-induced bladder tumour by 15 weeks, and
the mean latent period by 10 weeks (Table II). The
increased tumour incidence, reduced induction time
and potent hyperplastic activity of MSS (Tudor et
al., 1983) are all characteristic of the action of skin
promoters (Boutwell et al., 1982) and in an
operational sense, MMS clearly acts as a promoter
of carcinogenesis in the rat urinary bladder. In the
present experiment, however, as in many other
bladder promotion studies (see Hicks, 1983b), the
initiator (MNU) itself induced a significant
incidence of bladder tumours. The single dose of
0.3mg MNU was not a true initiating dose, but
proved to be a low carcinogenic dose. In this
situation, any compound which provides a
proliferative stimulus to the urothelium may be
expected to accelerate tumour development simply
by causing clonal expansion of MNU-induced
preneoplastic cells. The potent hyperplastic activity
of MMS no doubt provides such a stimulus and the
action of MMS in this system can be explained in
terms of Stage 2 promotion.
The 24% incidence of bladder neoplasia
produced by a single dose of 0.3mg MNU was
unexpected. The aliquots of MNU used in this
study were from the same batch as those used in
previous work with Wistar rats, in which doses up
to 0.5mg produced a bladder cancer incidence of
only 6% or less (Severs et al., 1982). The difference
may be attributable to the use of inbred F344 rats
for the present study instead of the outbred Wistars
used previously. Strain-related variations in
susceptibility of rats to individual carcinogens have
been recorded previously (Bralow et al., 1973;
Martin et al., 1974).
The production of a few tumours by MMS alone
shows it to be a complete, albeit weak, carcinogen.
In the mouse skin model also, long-term
applications of promoting agents including TPA
produced a few skin tumours (Roe, 1956; Boutwell
et al., 1957), and it is doubtful whether such a thing
as a "pure promoter" exists. Since MMS is capable
of binding covalently to DNA, it is to be expected
that it will have some initiating capacity. However,
unlike the potent complete bladder carcinogen
MNU, MMS is a comparitively weak alkylating
agent which causes predominantly N-methylation
with little 0-methylation of DNA residues (Lawley,
1976, 1980). It has been suggested that N-alkylation
is associated with cytotoxicity whereas 0-alkylation
is pro-mutagenic and hence initiating (Roberts et
al., 1974; Peterson et al., 1979) and thus it could be
predicted that MMS would have only weak
initiating activity. In any case, the possession of
initiating activity by a compound does not preclude
it from acting primarily as a promoter in a defined
situation, as demonstrated previously by Scribner
& Scribner (1980), with 7-bromo-methylbenz(a)
anthracene in the mouse skin model.
Theoretically MSS may also influence the
conversion of a benign tumour into an invasive74 R.J. TUDOR et al.
carcinoma, i.e. act at the final stage in a multistage
carcinogenesis system for MMS, like phorbol esters
(Kinsella & Radman, 1978; Fusenig & Dzarlieva,
1982), can bring about translocation of genetic
material by inducing chromosomal abberrations
and sister chromatid exchange (Perry & Evans,
1975). The presence of several carcinomas showing
an early invasive growth pattern in this multistage
model system is evidence that this may well be the
case.
Our results thus demonstrate that MMS is a
weak complete bladder carcinogen but in an
operational sense is a powerful promoting agent.
This implies that it has weak initiating activity, but
powerful late-stage carcinogenic potential. These
experiments do not provide any evidence about the
potency of MMS as a Stage 1 promoter in the
bladder, but they do show it to have late-stage
activity which may be attributable to its potent
mitogenic action on the urothelium. Its action in
the rat bladder is thus similar to that of 2-
acetylaminofluorene (2-AAF) on the mouse bladder
(Littlefield et al., 1979) and it appears to act
predominantly as a Stage 2 promoter in this
experimental multistage bladder cancer model.
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